Results 51 to 60 of about 4,750,590 (259)

Advanced Materials for Biologics Delivery to Brain Tumors

open access: yesAdvanced Materials, EarlyView.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng   +4 more
wiley   +1 more source

Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma

open access: yesNature Communications
Anti-CD38 monoclonal antibodies like Daratumumab (Dara) are effective in multiple myeloma (MM); however, drug resistance ultimately occurs and the mechanisms behind this are poorly understood.
Jiye Liu   +21 more
doaj   +1 more source

Histone H3K18 Lactylation Promotes the Malignant Progression of Wilms Tumor via a PSRC1/AKT/HIF‐1α Positive Feedback Loop

open access: yesAdvanced Science, EarlyView.
In nephroblastoma, aberrant glycolysis drives lactate accumulation, which elevates histone H3K18 lactylation via p300. Lactylation of the PSRC1 promoter activates its transcription. PSRC1 competitively binds AKT, relieving PTEN‐mediated inhibition and triggering AKT/mTOR/HIF‐1α signaling.
Yanping Wang   +6 more
wiley   +1 more source

Expansion Microscopy Reveals the Spatial Association of Therapeutic Antibody–Receptor Complexes With Cholesterol‐Rich Membrane Domains

open access: yesAngewandte Chemie, EarlyView.
We report a super‐resolution strategy that maps cholesterol‐rich membrane domains in whole, intact cells with an effective spatial resolution of ∼40 nm by combining expansion microscopy with a perfringolysin O domain 4 probe. This approach enables direct visualization of the spatial association between CD20 and CD38 complexes and cholesterol‐rich ...
Gang Wen   +9 more
wiley   +2 more sources

CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide

open access: yesNature Communications, 2020
CD229 is expressed on the surface of multiple myeloma cells, as well as B and T lymphocytes. Here, the authors engineer CD229-specific CAR T cells and, using patient samples and mouse models, show that treatment with these cells reduces tumour burden and
Sabarinath V. Radhakrishnan   +13 more
doaj   +1 more source

IFI27 and BAX are Essential for GSDME‐Mediated Myeloma Cell Pyroptosis

open access: yesAdvanced Science, EarlyView.
The proposed model of GSDME‐mediated MM cell pyroptosis modulated by IFI27 and BAX. IFI27 is downregulated in MM cells. Upon pyroptotic stimulation, such as DOX or ETO treatment, IFI27 is induced, therefore liberating BAX from BCL‐2 ❶. BAX is then recruited to mitochondria and forms homo‐oligomeric channels in OMM, therefore leading to cytochrome C ...
Yaoli Cui   +12 more
wiley   +1 more source

Generalizable Strategies for the Synthesis of Cereblon‐Recruiting PROTAC Prodrugs

open access: yesAngewandte Chemie, EarlyView.
Cereblon‐recruiting PROTACs remain challenging to derivatize for prodrug‐based delivery. In this study, three complementary conjugation strategies enabled the efficient synthesis of cleavable PROTAC prodrugs with tunable release kinetics that can be incorporated into a library of PEGylated constructs and bottlebrush prodrugs.
Aiden X. Wang   +7 more
wiley   +2 more sources

Carrier‐Free Berberine/Nitidine Chloride Self‐Assembled Nanoparticles Induce Ferroptosis to Overcome Bortezomib Resistance in Multiple Myeloma

open access: yesAdvanced Science, EarlyView.
A schematic illustrating the fabrication process and ferroptosis‐mediated therapeutic mechanism of carrier‐free self‐assembled BBR/NC‐SAPs for overcoming bortezomib resistance in multiple myeloma. ABSTRACT Therapeutic relapse driven by bortezomib resistance represents a formidable clinical barrier in the management of multiple myeloma (MM).
Yiwen Lv   +16 more
wiley   +1 more source

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

open access: yesFrontiers in Immunology, 2018
The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma (RRMM) was a critical advance for immunotherapies for multiple myeloma (MM ...
Shih-Feng Cho   +7 more
doaj   +1 more source

Corynoxine Inhibits Tumor Growth via Targeting NQO1 and Modulating the PTPA–NQO1/PP2A Switch to Activate PP2A

open access: yesAdvanced Science, EarlyView.
Corynoxine exerts potent broad‐spectrum anticancer activity by directly targeting NQO1. This interaction dissociates the oncogenic NQO1‐PTPA complex, releasing PTPA to robustly activate the tumor suppressor PP2A. Consequently, downstream Raf/MEK/ERK and PI3K/AKT signaling pathways are suppressed, downregulating c‐Myc and driving tumor regression ...
Guoqing Hou   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy